Loading ...
1997 Hyal Pharmaceutical Corporation Use of hyaluronic acid and formsto preventarterial restenosis
US5990095A - Use of hyaluronic acid and formsto preventarterial restenosis
US5614506A - Use of hyaluronic acid and formsto preventarterial restenosis
2000 - 02 - 08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and formsto preventarterial restenosis
Legal Events ( 8) External Links : USPTO , USPTO Assignment , EspacenetUse of hyaluronic acid and formsto preventarterial restenosis
Patent US6022866 - Use of hyaluronic acid and formsto preventarterial restenosis
Patent US20020077314 - Use of hyaluronic acid and formsto preventarterial restenosis
Norpharmco Inc. Use of hyaluronic acid and formsto preventarterial restenosis
Patent US5614506 - Use of hyaluronic acid and formsto preventarterial restenosis
Brevet US5990095 - Use of hyaluronic acid and formsto preventarterial restenosis
Patent US5990095 - Use of hyaluronic acid and formsto preventarterial restenosis
Sep 22 , 1993Feb 8 , 2000Hyal Pharmaceutical CorporationUse of hyaluronic acid and formsto preventarterial restenosisUS6043259
en ) 2000 - 02 - 08 Use of hyaluronic acid and formsto preventarterial restenosis
uses US5614506A ( en ) 1991 - 07 - 03 1997 - 03 - 25 Hyal Pharmaceutical Corporation Use of hyaluronic acid and formsto preventarterial restenosis
1989 - 09 - 21 1994 - 08 - 03 Use of hyaluronic acid and formsto preventarterial restenosis
en ) 1989 - 09 - 21 1993 - 09 - 22 Use of hyaluronic acid and formsto preventarterial restenosis
Thus according to another aspect of the invention , a process is provided for the prevention of arterial restenosis after balloon angioplasty in a human , the process comprising the administration of a therapeutically effective non - toxic amount of hyaluronic acid and/or salts thereof and/or homologues , analogues , derivatives , complexes , esters , fragments , and subunits of hyaluronic acid to the humanto preventarterial restenosis
US08448503 Expired - Lifetime US5990095A ( en ) 1989 - 09 - 21 1994 - 03 - 25 Use of hyaluronic acid and formsto preventarterial restenosis
In addition , Avitene ® because it comes in a light fluffy form , has been knownto occasionally causearterial embolization
mainly of aggregated platelets(passive) are composedArterial thrombi
US08996470 1989 - 09 - 21 1997 - 12 - 22 Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls Expired - Lifetime US6852708B2 ( en ) US08285764 US5614506A ( en ) 1991 - 07 - 03 1994 - 08 - 03 Use of hyaluronic acid and formsto preventarterial restenosis
injection of hyaluronic acid ( Restylane)Br J Dermatol 2002;146:928–9(passive) caused byArterial embolization
ES93203354 T ES2097972T3 ( en ) 1989 - 12 - 11 1990 - 12 - 11 Deviceto preventarterial restenosis
Protein S deficiency and homocysteinemiamay causearterial thromboses
primarily of platelets with little fibrin and few erythrocytes ( “ white ” thrombi(passive) are composedArterial thrombi
The company s products ... an oral agentto preventarterial restenosis
of aggregated platelets and antiplatelet medication(passive) are mainly composedArterial thrombi
of platelets adherent to ruptured endothelial surfaces(passive) are mostly composedArterial thromboses
vibration caused solely by industrial and occupational hazards(passive) caused byarterial hypertonia
the use of a pharmaceutical composition for the prevention of arterial restenosis after balloon angioplasty in a human is provided , the use being of a pharmaceutical composition comprising a therapeutically effective non - toxic amount of hyaluronic acid and/or salts and/or homologues , analogues , derivatives , complexes , esters , fragments , and subunits of hyaluronic acid in association with a suitable diluent , pharmaceutically acceptable carrier or other adjuvantsto preventarterial restenosis
the aircausesarterial hypocsemia
hypocapniacausesarterial vasoconstrictionIntracranial
A pseudoaneurysmmay causearterial emboli
injection of hyaluronic acid ( Restylanes(passive) caused byArterial embolization
The endovascular treatment was carried out under general anesthesia and systemic heparinizationto preventarterial thromboses
The intracranial intervention surgery was operated under general anesthesia , and also under systemic heparinizationto preventarterial thromboses
in- jection of hyaluronic acid ( Restylane(passive) caused byArterial embolization
the rupture of vessels(passive) caused byArterial haemorrhages
the injection of hyaluronic acid ( 4(passive) has also been caused byArterial embolization
the precise injection of the filler material into the artery(passive) is caused byArterial embolization
hemiplegia , aphasia , infarction of the bowel , kidney , lung , or ischemia or gangrene of arm or leg.2may causehemiplegia , aphasia , infarction of the bowel , kidney , lung , or ischemia or gangrene of arm or leg.2
usuallycausesusually
from atrial stasis and poorly adherent mural thrombi , which accounts for the most devastating complication : embolic strokeresultingfrom atrial stasis and poorly adherent mural thrombi , which accounts for the most devastating complication : embolic stroke
primarily of platelets bound by thin fibrin strandscomposedprimarily of platelets bound by thin fibrin strands
reduced oxygen release in tissue capillaries • Collagen fibers organisation & turnover improvement •will causereduced oxygen release in tissue capillaries • Collagen fibers organisation & turnover improvement •
in critical limb ischemiaresultingin critical limb ischemia
heart attacks and most strokescauseheart attacks and most strokes
in the heart or great vesselsmay originatein the heart or great vessels
serious disease by local ischemia ... whereas venous thrombi do so primarily by distant embolizationcauseserious disease by local ischemia ... whereas venous thrombi do so primarily by distant embolization
within the arterial system or within the left atrium or ventriclemay originatewithin the arterial system or within the left atrium or ventricle
acute heart attack or strokecan causeacute heart attack or stroke
serious disease ... venous thrombi , by giving rise to distant embolizationcauseserious disease ... venous thrombi , by giving rise to distant embolization
of aggregated platelets and venous thrombiare composedof aggregated platelets and venous thrombi
limb ischemia , myocardial infarction , and strokecausinglimb ischemia , myocardial infarction , and stroke
to local obstructive consequences ( in the vessels or heartleadto local obstructive consequences ( in the vessels or heart
serious disease by local blockade ... whereas venous thrombi do so primarily by distant blockade , or embolizationcauseserious disease by local blockade ... whereas venous thrombi do so primarily by distant blockade , or embolization
of materials that are often involved in cerebral embolicomposedof materials that are often involved in cerebral emboli
of platelet aggregates held together by fibrin ... while venous thrombi are composed of red cells and a larger amount of fibrin with relatively fewer plateletsare ... composedof platelet aggregates held together by fibrin ... while venous thrombi are composed of red cells and a larger amount of fibrin with relatively fewer platelets
complete occlusion of the vessel lumen leading to chronic ischemiacan also causecomplete occlusion of the vessel lumen leading to chronic ischemia
from an aneurysmal and thrombosed posterior circumflex humeral artery ( PCHA ) in the dominant shoulderoriginatingfrom an aneurysmal and thrombosed posterior circumflex humeral artery ( PCHA ) in the dominant shoulder
to transient ischemic attack ( TIA ) , stroke , myocardial infarction , angina , or abnormalities of the peripheral circulation that result in ischemia and gangrenecan leadto transient ischemic attack ( TIA ) , stroke , myocardial infarction , angina , or abnormalities of the peripheral circulation that result in ischemia and gangrene
to systemic embolism in patients with prosthetic heart valves or atrial fibrillation and death in patients with valvular heart diseasecan also contributeto systemic embolism in patients with prosthetic heart valves or atrial fibrillation and death in patients with valvular heart disease
of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood floware composedof predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow
to pressure- and depolarization - induced vasoconstrictionleadingto pressure- and depolarization - induced vasoconstriction
in increased vasoconstrictionresultingin increased vasoconstriction
hematology evaluation for hypercoagulable screeningpromptedhematology evaluation for hypercoagulable screening
increase in perfusion and total hemoglobincausesincrease in perfusion and total hemoglobin
to delayed symptomatology and high morbidity and mortality ratesleadsto delayed symptomatology and high morbidity and mortality rates
hypotension and reflex tachycardiacan causehypotension and reflex tachycardia
from an injured posterior circumflex humeral artery ( PCHAoriginatingfrom an injured posterior circumflex humeral artery ( PCHA
in acute strokes , ischemic limbs , or ischemic bowelresultingin acute strokes , ischemic limbs , or ischemic bowel
from the hemodynamic consequences of NO synthase blockade , such as increased blood pressure and reduced blood flowresultingfrom the hemodynamic consequences of NO synthase blockade , such as increased blood pressure and reduced blood flow
vasoconstriction and am suspicious that the perfusion pressure increases reported by others may have been caused by undetected obstruction of a major arterial branchcausesvasoconstriction and am suspicious that the perfusion pressure increases reported by others may have been caused by undetected obstruction of a major arterial branch
of atheromatous debris , fat , or coagulated erythrocytes , which are not expected to be influenced by antiplatelet agentscomposedof atheromatous debris , fat , or coagulated erythrocytes , which are not expected to be influenced by antiplatelet agents
in limb or cerebral ischaemiaresultingin limb or cerebral ischaemia
from an external uniform compressionresultingfrom an external uniform compression
to transient ischemic attacks and strokecontributeto transient ischemic attacks and stroke
alsocontributealso
to circulatory homeostasis and tissue perfusion by the flow / shear stress - dependent regulation of vascular resistance ( 21contributesto circulatory homeostasis and tissue perfusion by the flow / shear stress - dependent regulation of vascular resistance ( 21
a cerebral blood flow decreasecausesa cerebral blood flow decrease